Oxandrolone first came out in 1962. The original intention of Oxandrolone was to achieve maximum safety, so that women and children can use it safely. This is also true in clinical practice. Men, women and children have shown extremely high tolerance. It has achieved wide-ranging clinical success. Oxandrolone has been used to promote postoperative lean body mass gain, trauma treatment, glucocorticoid disorders, increase bone density in patients with osteoporosis, and slow development of childhood adolescence.
The most important thing about Oxandrolone is to increase the ability of muscle nitrogen retention, reduce sex hormone binding globulin (SHBG) and inhibit glucocorticoids. An increase in nitrogen retention will promote anabolic capacity, because reducing the level of nitrogen retention usually results in a catabolic state. The reduction in SHBG will produce higher levels of free testosterone in the body, promoting the free or unbound state of all circulating anabolic steroids. Simply put, this makes the use of steroids more effective.
Some studies even Oxandrolone has been shown to directly promote lipolysis. Many people believe that it can firmly bind to the androgen receptor, and reduce the ability of thyroid binding globulin, as well as increase the binding of thyroxine from the protein. This effect leads to higher utilization of triiodothyronine hormone or T3 hormone.
Oxandrolone is known as a good agent that promotes strength and increases muscle mass, although the mild nature of the compound makes it less than ideal for swelling purposes. Among bodybuilders, the most commonly used training is in the cutting phase. Oxandrolone can be combined with anabolics such as Metenolone, Stanozolol, Mesterosterone, etc. to obtain a stronger and more defined appearance. This combination very popular.
We can’t call Oxandrolone as a very powerful anabolic steroid. However, we can call it very beneficial. When we consider its generally good tolerability, it becomes one of the most valuable anabolic alcohols of all time.